-

Barclays PLC (BCS) Investor Notice: Robbins LLP Reminds Investors of Class Action Against Barclays PLC

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Barclays PLC (NYSE: BCS) securities between July 22, 2019 and October 12, 2023. Barclays is a British universal bank.

For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What is this Case About: Barclays PLC (BCS) Misled Investors About the Relationship Between its CEO and Jeffrey Epstein

According to the complaint, during the class period, defendants failed disclose that contrary to his false public assertions, James Staley (Barclays former CEO) had a close relationship with Jeffrey Epstein and was reportedly aware of Jeffrey Epstein’s criminal activities and may have even sexually assaulted a victim who had previously been trafficked by Jeffrey Epstein. If discovered, Staley's close, personal relationship with Jeffrey Epstein and potential criminal activity could bring reputational, legal, and financial harm to Barclays. As a result, Barclays response to the British Financial Conduct Authority's (FCA's) inquiry regarding Staley’s relationship with Epstein was materially false. When Barclays became aware of information contradicting its response to the FCA inquiry, it failed to update the response so that it would be accurate, or otherwise take any meaningful action. As the truth of Staley's involvement with Epstein was revealed, the price of Barclay's shares declined.

What Now: Similarly situated shareholders may be eligible to participate in the class action against Barclays PLC. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP. Plaintiffs must file their lead plaintiff papers by January 2, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against Barclays PLC settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:BCS

Release Summary
Barclays PLC (BCS) Misled Investors About the Relationship Between its CEO and Jeffrey Epstein
Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Erasca, Inc. Class Action Reminder - Robbins LLP Encourages ERAS Stockholders to Contact the Firm for Information About Their Rights  

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025 and April 26, 2026. Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

ADMA Biologics, Inc. Stock Drop: Robbins LLP Urges Investors to Contact the Firm for Information About the Class Action Against ADMA Biologics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026. ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. For more information...

VIA Transportation, Inc. Stock Drop: Harmed Investors Should Contact Robbins LLP for Information About Leading the Class Action Against VIA

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Via Transportation, Inc. (NYSE: VIA) in connection with the Company's September 15, 2025 initial public statement ("IPO"). Via Transportation, Inc. provides a platform that transforms global transportation systems into digital networks in the United States, Germany, and internationally.For more information, submit a form, email attorney Aaron D...
Back to Newsroom